Researchers develop ACBI3, a KRAS mutation-targeting drug, offering improved treatment for 17-25% of cancers.

Researchers at the University of Dundee and Boehringer Ingelheim have developed ACBI3, a drug that targets KRAS mutations, which occur in 17-25% of cancers. ACBI3, a PROTAC, can eliminate 13 of the 17 common KRAS mutants, offering a more effective treatment approach than current options. The compound will be available for free through Boehringer Ingelheim's opnMe portal to facilitate further research on this critical cancer target.

September 23, 2024
3 Articles